HGH 191AA dosage chart

10IU Vial

HGH 191AA is dosed at 200 mcg–900 mcg daily via subcutaneous injection in educational protocols. A 10IU vial reconstituted with bacteriostatic water yields about 1.11 mg/mL. This information is for research and educational use only.

Reconstitute: Add 3.0 mL bacteriostatic water → ~1.11 mg/mL concentration (~1111 mcg/mL).
Typical daily range: 150–500 mcg (conservative replacement protocols) to 1000–2000 mcg (advanced metabolic studies).
Easy measuring: At 1.11 mg/mL, 1 unit = 0.01 mL ≈ 11.1 mcg on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

Dosing schedule

Week	Daily Dose (mcg)	Units (per injection) (mL)
Week 1	200 mcg	18 units (0.18 mL)
Week 2	300 mcg	27 units (0.27 mL)
Week 3	400 mcg	36 units (0.36 mL)
Week 4	500 mcg	45 units (0.45 mL)
Week 5	600 mcg	54 units (0.54 mL)
Week 6	700 mcg	63 units (0.63 mL)
Week 7	800 mcg	72 units (0.72 mL)
Week 8	900 mcg	81 units (0.81 mL)

Extended 12-Week Protocol (Optional)

Week	Daily Dose (mcg)	Units (per injection) (mL)
Week 9	1000 mcg	90 units (0.90 mL)
Week 10	1100 mcg	99 units (0.99 mL)
Week 11	1200 mcg	108 units (1.08 mL)
Week 12	1300 mcg	117 units (1.17 mL)

Reconstitution steps

1Draw 3.0 mL bacteriostatic water with a sterile syringe.
2Inject slowly down the vial wall; avoid foaming.
3Gently swirl/roll until dissolved (do not shake vigorously to preserve protein structure).
4Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Important Notes

Practical considerations for consistency and safety.

Use new sterile insulin syringes for each injection; dispose in a sharps container.
Rotate injection sites systematically (abdomen, thighs, upper arms) to reduce local irritation and prevent lipoatrophy.
Inject slowly; wait a few seconds before withdrawing the needle to minimize leakage.
Document daily dose, injection site, and any observed effects to maintain consistency and track tolerance.
FDA-approved Genotropin is a 191-amino-acid somatropin product supplied as a lyophilized powder for subcutaneous injection after product-specific reconstitution. Those instructions apply to that approved formulation and device.

How This Works

HGH 191AA is recombinant human growth hormone (somatropin) that is structurally identical to endogenous GH secreted by the pituitary gland. Clinical studies demonstrate that GH administration promotes increases in lean body mass, reductions in adipose tissue, and improvements in body composition through multiple mechanisms including enhanced lipolysis, increased protein synthesis, and stimulation of IGF-1 production. Pivotal research by Rudman and colleagues showed that six months of HGH administration in older men significantly increased lean body mass and decreased adipose mass compared to placebo. Long-term follow-up studies in adults with GH deficiency have demonstrated sustained improvements in muscle strength and body composition with maintenance dosing.

Subcutaneous administration once daily, particularly at bedtime, is designed to mimic physiological patterns of endogenous GH secretion. Dosing protocols vary based on therapeutic goals: conservative replacement protocols typically employ 150–500 mcg daily, while advanced metabolic and performance research protocols may utilize 1000–2000 mcg daily. Higher doses produce more pronounced physiological effects but also carry increased risk of side effects including fluid retention, joint discomfort, and potential metabolic disturbances.

Potential Benefits & Side Effects

Observations from clinical research literature.

Note: While research in healthy athletes showed GH increased lean body mass, it did not significantly improve muscle strength or exercise performance in systematic reviews. Side effects and benefits are dose-dependent, with higher doses yielding more pronounced effects but also increased risk profiles.

Increases in lean body mass and reductions in adipose tissue in clinical studies.
Enhanced fat oxidation and lipolysis in dose-dependent manner.
Sustained improvements in muscle strength and body composition with long-term use in GH-deficient adults.
Improved metabolic parameters in appropriate clinical contexts.
Injection site reactions (redness, irritation); can be minimized by proper rotation technique.
Fluid retention and peripheral edema, particularly at higher doses.
Joint discomfort or arthralgias reported in some clinical protocols.
Potential glucose metabolism effects; monitoring may be warranted in extended protocols.
Risk of lipoatrophy at injection sites if rotation is inadequate.

Lifestyle Factors

Complementary strategies for optimizing outcomes.

Maintain adequate protein intake (1.6–2.2 g/kg body weight) to support anabolic processes stimulated by GH.
Combine resistance training and progressive overload to maximize lean mass gains and strength improvements.
Include cardiovascular activity to enhance metabolic adaptations and fat oxidation.
Prioritize sleep quality and duration (7–9 hours) to support endogenous recovery processes.
Manage stress and cortisol levels, as chronic stress can interfere with GH signaling and metabolic outcomes.
Ensure adequate hydration, particularly at higher doses where fluid retention may occur.

Injection Technique

Subcutaneous injection guidance from clinical best-practice resources.

Clean the vial stopper and injection site with alcohol; allow to air dry completely.
Pinch a skinfold at the injection site; insert the needle at 45–90° into subcutaneous tissue.
Do not aspirate for subcutaneous injections; inject slowly and steadily.
Rotate sites systematically (abdomen, thighs, upper arms) to prevent lipohypertrophy and lipoatrophy.
Common subcutaneous sites: abdomen (at least 2 inches from navel), outer thighs, upper arms (posterior surface).
Wait a few seconds after injection before withdrawing needle to minimize solution leakage.

important-note

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. HGH 191AA is a research peptide. Always consult qualified healthcare professionals before beginning any peptide protocol.

HGH 191AA dosage FAQs

How much bacteriostatic water do you use to reconstitute HGH 191AA?

Add 3.0 mL bacteriostatic water → ~1.11 mg/mL concentration (~1111 mcg/mL). for a 10IU Vial vial. Add the water slowly against the inside wall of the vial and swirl — never shake — until the powder fully dissolves.

What does the HGH 191AA dosing schedule look like?

Week 1 — 200 mcg — 18 units (0.18 mL); Week 2 — 300 mcg — 27 units (0.27 mL); Week 3 — 400 mcg — 36 units (0.36 mL); Week 4 — 500 mcg — 45 units (0.45 mL). The full table above lists every step with matching syringe units.

What are the mixing steps for HGH 191AA?

Draw 3.0 mL bacteriostatic water with a sterile syringe. Inject slowly down the vial wall; avoid foaming. Gently swirl/roll until dissolved (do not shake vigorously to preserve protein structure).

How should reconstituted HGH 191AA be stored?

Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles..

How many insulin syringe units equal a HGH 191AA dose?

Units depend on the water volume you used. Divide your target dose by the vial concentration to get millilitres, then multiply by 100 — 1 unit on a U-100 insulin syringe is 0.01 mL. The Spartan Peptides reconstitution calculator does this conversion for you.

Is HGH 191AA approved for human use?

No. HGH 191AA is sold and referenced strictly as a research chemical. Nothing on this page is medical advice and the material is not for human consumption.

Educational and research information only. Not medical advice, not for human consumption. Values are reference figures — always verify your own math with the reconstitution calculator.

On any insulin syringe, 1 unit = 0.01 mL, so unit counts above hold across brands.